Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integer Holdings ( (ITGR) ) has issued an announcement.
On April 30, 2026, Integer Holdings reported first-quarter 2026 results broadly in line with prior guidance, posting 0.5% sales growth to $440 million and 1.3% organic growth, but a 36% drop in GAAP operating income and a 14% decline in adjusted operating income amid previously flagged headwinds tied to three new products and weakness in Other Markets. While Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation logged modest sales gains, rising debt pushed leverage to 3.2 times adjusted EBITDA and the company cut its 2026 outlook, now expecting slight revenue contraction and lower adjusted profitability versus 2025, even as management maintains that pressures are temporary and reiterates a target of resuming above-market organic growth in 2027.
The most recent analyst rating on (ITGR) stock is a Hold with a $92.00 price target. To see the full list of analyst forecasts on Integer Holdings stock, see the ITGR Stock Forecast page.
Spark’s Take on ITGR Stock
According to Spark, TipRanks’ AI Analyst, ITGR is a Neutral.
Overall score reflects solid financial performance (steady growth and positive cash generation, albeit with rising debt and uneven margins) as the primary driver. The score is tempered by mixed technicals (below the 200DMA, neutral momentum) and a mid-to-higher P/E with no dividend support, while the earnings call adds a modest positive tilt due to strong 2025 execution but clear near-term 2026 growth and margin headwinds.
To see Spark’s full report on ITGR stock, click here.
More about Integer Holdings
Integer Holdings Corporation, based in Plano, Texas, operates in the medical technology sector as a leading manufacturer of cardio and vascular devices, cardiac rhythm management and neuromodulation products, and other specialized medical components. The company focuses on supplying OEMs with advanced medical device solutions and has been exiting certain lower-priority portable medical markets since a multi-year wind-down announced in 2022.
On April 30, 2026, Integer reported first-quarter 2026 results broadly in line with its earlier guidance, with sales up 0.5% to $440 million and organic growth of 1.3%, but with notable profit pressure as GAAP operating income fell 36% and adjusted operating income declined 14% year-on-year. Segment performance was mixed, with modest growth in Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation offset by sharp weakness in Other Markets, while leverage rose to 3.2 times adjusted EBITDA and the company trimmed its 2026 outlook ranges to reflect headwinds from three new products and other market dynamics.
Integer now projects 2026 sales to decline 1% to 3% versus 2025 and expects adjusted EBITDA and adjusted net income to be below last year, even as GAAP net income and EPS are forecast to grow, highlighting the impact of amortization, restructuring, acquisition and ERP-related charges on reported versus adjusted metrics. Management stressed that the headwinds are temporary, reaffirming plans for higher-margin growth and a return to organic sales expansion at least 200 basis points above the market in 2027, with capital spending and leverage managed within targeted ranges.
Average Trading Volume: 784,016
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.85B
Find detailed analytics on ITGR stock on TipRanks’ Stock Analysis page.